A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
18 Years and older, Male and Female
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
The dose escalation part (Part A) of the study will evaluate the safety and tolerability of
escalating doses of CC-93269, administered intravenously (IV), to determine the maximum
tolerated dose (MTD) and non-tolerated dose (NTD) of both the first dose and subsequent doses
of CC-93269. The expansion part (Part B) will further evaluate the safety and efficacy of
CC-93269 administered at or below the MTD in selected expansion cohorts in order to determine
the recommended Phase 2 dose (RP2D). One or more dosing regimens may be selected for cohort
expansion. All treatments will be administered in 28-day cycles for up to 2 years until
confirmed disease progression, unacceptable toxicity, or subject/Investigator decision to